386 related articles for article (PubMed ID: 32212912)
1. Clinical Potential of Targeting Fibroblast Growth Factor-23 and αKlotho in the Treatment of Uremic Cardiomyopathy.
Law JP; Price AM; Pickup L; Radhakrishnan A; Weston C; Jones AM; McGettrick HM; Chua W; Steeds RP; Fabritz L; Kirchhof P; Pavlovic D; Townend JN; Ferro CJ
J Am Heart Assoc; 2020 Apr; 9(7):e016041. PubMed ID: 32212912
[TBL] [Abstract][Full Text] [Related]
2. αKlotho attenuates cardiac hypertrophy and increases myocardial fibroblast growth factor 21 expression in uremic rats.
Suassuna PGA; Cherem PM; de Castro BB; Maquigussa E; Cenedeze MA; Lovisi JCM; Custódio MR; Sanders-Pinheiro H; de Paula RB
Exp Biol Med (Maywood); 2020 Jan; 245(1):66-78. PubMed ID: 31847589
[TBL] [Abstract][Full Text] [Related]
3. New Insights into the Role of FGF-23 and Klotho in Cardiovascular Disease in Chronic Kidney Disease Patients.
Memmos E; Papagianni A
Curr Vasc Pharmacol; 2021; 19(1):55-62. PubMed ID: 32310050
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotective Effects of Paricalcitol Alone and in Combination With FGF23 Receptor Inhibition in Chronic Renal Failure: Experimental and Clinical Studies.
Czaya B; Seeherunvong W; Singh S; Yanucil C; Ruiz P; Quiroz Y; Grabner A; Katsoufis C; Swaminathan S; Abitbol C; Rodriguez-Iturbe B; Faul C; Freundlich M
Am J Hypertens; 2019 Jan; 32(1):34-44. PubMed ID: 30329020
[TBL] [Abstract][Full Text] [Related]
5. Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy.
Hu MC; Shi M; Gillings N; Flores B; Takahashi M; Kuro-O M; Moe OW
Kidney Int; 2017 May; 91(5):1104-1114. PubMed ID: 28131398
[TBL] [Abstract][Full Text] [Related]
6. Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate.
Xie J; Yoon J; An SW; Kuro-o M; Huang CL
J Am Soc Nephrol; 2015 May; 26(5):1150-60. PubMed ID: 25475745
[TBL] [Abstract][Full Text] [Related]
7. αKlotho and Chronic Kidney Disease.
Neyra JA; Hu MC
Vitam Horm; 2016; 101():257-310. PubMed ID: 27125746
[TBL] [Abstract][Full Text] [Related]
8. αKlotho and vascular calcification: an evolving paradigm.
Hu MC; Kuro-o M; Moe OW
Curr Opin Nephrol Hypertens; 2014 Jul; 23(4):331-9. PubMed ID: 24867676
[TBL] [Abstract][Full Text] [Related]
9. The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy.
Grabner A; Faul C
Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):314-24. PubMed ID: 27219043
[TBL] [Abstract][Full Text] [Related]
10. Deficiency of Soluble α-Klotho as an Independent Cause of Uremic Cardiomyopathy.
Xie J; Wu YL; Huang CL
Vitam Horm; 2016; 101():311-30. PubMed ID: 27125747
[TBL] [Abstract][Full Text] [Related]
11. FGF23 and Klotho in chronic kidney disease.
Olauson H; Larsson TE
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):397-404. PubMed ID: 23666415
[TBL] [Abstract][Full Text] [Related]
12. Cardiac Remodeling in Chronic Kidney Disease.
Kaesler N; Babler A; Floege J; Kramann R
Toxins (Basel); 2020 Mar; 12(3):. PubMed ID: 32150864
[TBL] [Abstract][Full Text] [Related]
13. Kidney fibroblast growth factor 23 does not contribute to elevation of its circulating levels in uremia.
Mace ML; Gravesen E; Nordholm A; Hofman-Bang J; Secher T; Olgaard K; Lewin E
Kidney Int; 2017 Jul; 92(1):165-178. PubMed ID: 28341272
[TBL] [Abstract][Full Text] [Related]
14. Vasculopathy in the setting of cardiorenal syndrome: roles of protein-bound uremic toxins.
Guo J; Lu L; Hua Y; Huang K; Wang I; Huang L; Fu Q; Chen A; Chan P; Fan H; Liu ZM; Wang BH
Am J Physiol Heart Circ Physiol; 2017 Jul; 313(1):H1-H13. PubMed ID: 28411233
[TBL] [Abstract][Full Text] [Related]
15. CB1 cannabinoid receptor antagonist attenuates left ventricular hypertrophy and Akt-mediated cardiac fibrosis in experimental uremia.
Lin CY; Hsu YJ; Hsu SC; Chen Y; Lee HS; Lin SH; Huang SM; Tsai CS; Shih CC
J Mol Cell Cardiol; 2015 Aug; 85():249-61. PubMed ID: 26093151
[TBL] [Abstract][Full Text] [Related]
16. The guanylate cyclase C agonist linaclotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease.
Nanto-Hara F; Kanemitsu Y; Fukuda S; Kikuchi K; Asaji K; Saigusa D; Iwasaki T; Ho HJ; Mishima E; Suzuki T; Suzuki C; Tsukimi T; Matsuhashi T; Oikawa Y; Akiyama Y; Kure S; Owada Y; Tomioka Y; Soga T; Ito S; Abe T
Nephrol Dial Transplant; 2020 Feb; 35(2):250-264. PubMed ID: 31411705
[TBL] [Abstract][Full Text] [Related]
17. Sodium potassium adenosine triphosphatase (Na/K-ATPase) as a therapeutic target for uremic cardiomyopathy.
Wang X; Liu J; Drummond CA; Shapiro JI
Expert Opin Ther Targets; 2017 May; 21(5):531-541. PubMed ID: 28338377
[TBL] [Abstract][Full Text] [Related]
18. A Land of Controversy: Fibroblast Growth Factor-23 and Uremic Cardiac Hypertrophy.
Bao JF; Hu PP; She QY; Li A
J Am Soc Nephrol; 2020 Jul; 31(7):1423-1434. PubMed ID: 32527977
[TBL] [Abstract][Full Text] [Related]
19. Uremic Cardiomyopathy: A New Piece in the Chronic Kidney Disease-Mineral and Bone Disorder Puzzle.
de Albuquerque Suassuna PG; Sanders-Pinheiro H; de Paula RB
Front Med (Lausanne); 2018; 5():206. PubMed ID: 30087898
[TBL] [Abstract][Full Text] [Related]
20. Extrarenal effects of FGF23.
Haffner D; Leifheit-Nestler M
Pediatr Nephrol; 2017 May; 32(5):753-765. PubMed ID: 27704252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
